Pulmonary Embolism CTPA Interpretation: Case-Based Radiology Guide

Several artifacts can lead to false-positive PE diagnoses on CTPA. Motion artifact is the most common pitfall, particularly affecting segmental and sub-segmental branches; switching to lung window can reveal motion-related abnormalities. Beam hardening artifact from dense contrast material can mimic filling defects in adjacent vessels. Flow-related artifacts occur when non-opacified blood from the IVC mixes with opacified blood, creating apparent filling defects. Recognizing these pitfalls prevents unnecessary anticoagulation and reduces diagnostic errors.

CT pulmonary angiograms can show artifacts and mimics that simulate pulmonary embolism, including mixing artifacts from early imaging (appearing as wispy, ill-defined filling defects), bronchial artery inflow in chronic lung disease, motion artifacts, mucus plugs, pulmonary veins, lymph nodes, and stump thrombus after lobectomy; these can be distinguished by repeating the scan with delayed imaging triggered from the aorta, using multiplanar reformats, examining lung windows, and tracing filling defects to their anatomical origin.

This section advances CTPA interpretation skills through artifact recognition, differentiation from anatomical mimics, and detection of subtle pulmonary emboli. Five main limitations affect CTPA quality: suboptimal contrast opacification, transient interruption from deep breath, pulmonary motion artifact, SVC streak artifact, and image noise. Problem-solving strategies include breath hold coaching, high pitch protocols, reduced contrast for large body habitus, dual-energy CT, and delayed technique. Distinguishing PE from artifacts relies on key features: acute PE has well-defined margins while artifact has ill-defined margins; acute PE is longitudinally oriented while artifact may be oblique/perpendicular; ROI >78 HU on standard CT is typically artifact. Anatomic mimics include pulmonary veins (trace to left atrium), mucoid impacted bronchi (lung windows), and perivascular lymph nodes at hilum/branch points. Bronchial artery inflow artifact produces convex lunar-shaped filling defects with distal non-opacification. For subtle PE detection, perform careful search for abrupt density changes, confirm with sharp lung algorithm series, invert soft tissue window, and use coronal/sagittal planes. Isolated subsegmental PE occurs in ~9% of positive exams and requires careful evaluation to avoid overdiagnosis.

This section covers systematic identification of artifacts that mimic pulmonary embolism. Common artifacts include suboptimal contrast opacification (<250 HU ROI), transient interruption from unopacified blood during deep breath, pulmonary motion artifact (blurred vessels on lung windows), streak artifact radiating from SVC, and image noise in large body habitus. Additional limitations include flow-related artifact (wispy, ill-defined margins), low cardiac output (poor peripheral opacification), parenchymal disease (focal non-opacification), and bronchial artery inflow artifact (convex lunar shape in non-dependent lobes). Mimics include pulmonary veins (traced to left atrium), mucoid impaction bronchi (lung window appearance), and hilar lymph nodes. Diagnostic tools include lung window examination, coronal/sagittal correlation, ROI analysis, and artifact recognition patterns.

Motion artifacts are the leading cause of false-positive PE diagnoses. Respiratory motion causes ghosting where vessels blur and superimpose, mimicking filling defects. Contrast timing errors—too early (dense SVC/pulmonary artery, minimal aorta) or too late (washed-out pulmonary arteries)—both compromise diagnostic accuracy. Transient interruption of contrast occurs when patients bear down during breath-hold, causing unopacified blood to wash out the pulmonary artery tree. Contrast mixing mimics thrombus when fast scanning or poor cardiac function outrun the bolus, or when slow flow occurs in diseased lung parenchyma. Bronchial artery inflow through anastomoses can also mimic PE. Image processing artifacts from metallic hardware, mucus plugging, pulmonary venous streaming, and edge-enhancing algorithms can all simulate filling defects.

Pulmonary embolism (PE) is a life-threatening condition where a thrombus lodges in the pulmonary artery, causing blood supply cutoff to the lung; CT pulmonary angiography (CTPA) is the gold standard imaging modality for diagnosis, showing direct signs like intraluminal filling defects, polom sign, railway track sign, and saddle thrombus, while V/Q scan serves as an alternative for patients contraindicated for CTPA, and echocardiography is used for risk stratification in unstable patients, with imaging-based classification dividing PE into massive (hemodynamic collapse), submassive (right heart strain with normal BP), and low-risk categories to guide management.

PE risk stratification has evolved from simple 'massive' and 'submassive' classifications to a mortality-based system: low-risk (stable, normal BP, no RV dysfunction, mortality <3.5%), intermediate-risk (normal BP but RV dysfunction, mortality 6.7-7%), and high-risk (hypotension with RV dysfunction, mortality ~60%). The clinical decision algorithm follows: (1) Low suspicion with negative PERC and Wells score → PE excluded; (2) High suspicion with no alternative diagnosis → immediate CT angiography; (3) Intermediate suspicion or positive Wells score → D-dimer testing (threshold 500 ng/mL for Wells ≤4, age-adjusted for Wells >4). Diagnostic imaging includes: Chest X-ray (Hampton's hump, Westermark sign, enlarged pulmonary artery), CT angiography (saddle embolus, segmental/subsegmental emboli, pulmonary infarction), and ECG (S1Q3T3 pattern, right bundle branch block, right axis deviation). Right ventricular dysfunction assessment uses: RV/LV diameter ratio (normal <0.9, abnormal ≥0.9), TAPSE <16 mm, and tricuspid regurgitation velocity <9.5 cm/s. These findings indicate significant right ventricular strain and correlate with mortality risk.

This video explains the evolution from the outdated massive/submassive classification of pulmonary embolism to the modern ABCDE staging system (plus respiratory modifier R), which categorizes patients from asymptomatic incidental PE (Stage A) to extreme cardiopulmonary failure (Stage E). The risk stratification integrates clinical history, physical examination, biomarkers (troponin, proBNP, lactate), and imaging (RV dysfunction, RV/LV ratio), with mean arterial pressure below 80 mmHg being the single most important prognostic marker. Clinical scores like PESI/sPESI and Hestia help determine outpatient versus admission disposition, while Bova and NEWS2 predict in-hospital deterioration and ICU needs, ultimately guiding therapy intensity from standard anticoagulation to thrombolytic or catheter-directed interventions.

Pulmonary embolism is pulmonary artery obstruction, most commonly from lower limb DVT. Risk factors: acquired (surgery, trauma, immobilization, pregnancy, estrogen-containing contraceptives), inherited (factor V Leiden, protein C/S deficiency, antithrombin III deficiency). Risk stratification: massive PE (hypotension + RV dysfunction, high mortality), submassive PE (normal BP but RV dysfunction), low-risk PE. Clinical features: dyspnea (most common), tachypnea, tachycardia, hypotension, elevated JVP, loud P2. ECG: sinus tachycardia (most common), S1Q3T3 pattern, right bundle branch block. Chest X-ray: Hampton hump, Westermark sign. Initial investigation: CTPA for stable patients; V/Q scan alternative. Treatment: massive PE - thrombolysis + anticoagulation; submassive PE - anticoagulation alone; recurrent PE - IVC filter. Complications: RV failure, chronic thromboembolic pulmonary hypertension.

PE risk stratification uses three categories: low risk (PESI score 0, no RV dysfunction, no elevated biomarkers), intermediate risk (PESI >0 with either RV dysfunction or elevated biomarkers), and high risk (shock/hypotension). Imaging modalities include CT pulmonary angiography (preferred due to availability and additional diagnostic information) and V/Q scan (preferred for pregnant patients and those with iodine allergy). Echocardiography serves for risk stratification and diagnosis in shock patients.

Advanced therapies for pulmonary embolism include systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy, and surgical embolectomy. Systemic thrombolysis plus anti-coagulation is recommended for Categories E1-E2 with acceptable bleeding risk. Catheter-directed thrombolysis plus anti-coagulation is reasonable for Categories C2-C3, D1-D2, and E1. Mechanical thrombectomy plus anti-coagulation is reasonable for Categories C2-C3, D1-D2, and E1. Surgical embolectomy plus anti-coagulation is reasonable for Categories D1-D2 and E1-E2. For acute pulmonary embolism without contraindications, anti-coagulation should be initiated. Low molecular weight heparin is recommended over unfractionated heparin for initial parenteral therapy in Categories C1-E1. Direct oral anticoagulants are preferred over vitamin K antagonists for eligible patients. Special populations require tailored approaches: pregnancy requires LMWH or UFH; breastfeeding patients should use LMWH, UFH, or warfarin; cancer patients may use DOACs over LMWH to reduce intracranial hemorrhage risk.

For high-risk PTE, anticoagulation begins immediately with thrombolytic therapy options: systemic thrombolysis (most effective for high-risk, limited for low-risk), surgical embolectomy (for hemodynamically unstable patients with low bleeding risk), and catheter-directed thrombolysis (increasingly preferred with level 2A evidence). Catheter-directed approaches use ultrasound-guided fragmentation and selective thrombolysis, reducing drug dosage by 4-fold. Systemic thrombolysis is contraindicated in recent intracranial hemorrhage and active bleeding.

Pulmonary embolism management is guided by risk stratification: low-risk patients (hemodynamically stable, no RV dysfunction, normal troponin/BNP) receive outpatient anticoagulation with DOACs; intermediate-low risk patients (stable with either mild RV dysfunction or elevated biomarkers) also receive anticoagulation; intermediate-high risk patients (both RV dysfunction and elevated biomarkers) may require mechanical thrombectomy or catheter-directed thrombolysis; and high-risk/massive PE patients (hemodynamically unstable, hypotensive, shock) require systemic thrombolysis with TPA as first-line therapy, with ECMO and surgical embolectomy as alternatives if thrombolysis fails or is contraindicated.

Intracardiac thrombi (2-4% of cases) increase mortality 2.26-fold. Treatment options include systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy, or surgical embolectomy for refractory cases. Systemic thrombolysis with alteplase 100 mg over 2 hours is standard for refractory PE shock. In refractory shock (Category E), thrombolysis reduces mortality 47% despite 9.9% major bleeding risk. In hemodynamically unstable patients (Categories C3-D2), thrombolysis reduces mortality 47% with 4.6% bleeding risk. Standard anticoagulation duration is 3-6 months, especially with reversible risk factors. Extended anticoagulation requires individualized risk-benefit assessment for persistent non-reversible risks. Persistent dyspnea beyond 3 months requires evaluation for chronic thromboembolic pulmonary hypertension (CTEPH). Diagnostic evaluation includes echocardiogram, V/Q scanning, and cardiopulmonary exercise testing. Approximately 4-10% of PE patients have underlying cancer, particularly without reversible risk factors; screening should include thorough history, physical exam, and age-appropriate protocols. Thrombophilia testing should be deferred during acute hospitalization due to altered acute-phase reactants.

There is essentially no high-quality randomized controlled trial evidence comparing catheter-directed thrombolysis, mechanical thrombectomy, or surgical embolectomy to systemic thrombolysis for high-risk PE. The PEITHO trial showed no difference between catheter-directed and mechanical thrombectomy. Most supporting evidence comes from observational studies funded by device manufacturers, which lack control groups. While these interventions may seem physiologically reasonable (removing the clot directly), there is currently insufficient evidence to recommend them over systemic thrombolysis. They should be reserved for patients with absolute contraindications to systemic thrombolysis who cannot wait for definitive treatment.